🟢 Moleculin Biotech is trading 6.57% up today with no confirmed company-specific catalyst identified

Moleculin Biotech is trading 6.57% higher at $0.72, with no confirmed company-specific catalyst identified for September 4, 2026.

• Updates focus on the MIRACLE trial’s planned 90-patient enrollment milestone in September and expected unblinded efficacy readout between December 2026 and February 2027, not a new announcement.
• With broader markets mixed to lower and no matching catalyst or supportive trend, attribution remains limited.
• Shares rose 6.77% on September 2 and fell 2.67% on September 3.